Browse TLR1

Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Cytoplasmic vesicle, phagosome membrane Single-pass type I membrane protein Membrane raft Golgi apparatus Note=Does not reside in lipid rafts before stimulation but accumulates increasingly in the raft upon the presence of the microbial ligand. In response to triacylated lipoproteins, TLR2:TLR1 heterodimers are recruited in lipid rafts, this recruitment determine the intracellular targeting to the Golgi apparatus.
Domain PF13855 Leucine rich repeat
PF01463 Leucine rich repeat C-terminal domain
PF01582 TIR domain
Function

Participates in the innate immune response to microbial agents. Specifically recognizes diacylated and triacylated lipopeptides. Cooperates with TLR2 to mediate the innate immune response to bacterial lipoproteins or lipopeptides (PubMed:21078852). Forms the activation cluster TLR2:TLR1:CD14 in response to triacylated lipopeptides, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway (PubMed:16880211). Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002224 toll-like receptor signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002274 myeloid leukocyte activation
GO:0002755 MyD88-dependent toll-like receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0009306 protein secretion
GO:0009595 detection of biotic stimulus
GO:0016045 detection of bacterium
GO:0031349 positive regulation of defense response
GO:0032490 detection of molecule of bacterial origin
GO:0032493 response to bacterial lipoprotein
GO:0032635 interleukin-6 production
GO:0032640 tumor necrosis factor production
GO:0032675 regulation of interleukin-6 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032755 positive regulation of interleukin-6 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0034130 toll-like receptor 1 signaling pathway
GO:0038123 toll-like receptor TLR1:TLR2 signaling pathway
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042116 macrophage activation
GO:0042226 interleukin-6 biosynthetic process
GO:0042494 detection of bacterial lipoprotein
GO:0042495 detection of triacyl bacterial lipopeptide
GO:0042533 tumor necrosis factor biosynthetic process
GO:0042534 regulation of tumor necrosis factor biosynthetic process
GO:0042535 positive regulation of tumor necrosis factor biosynthetic process
GO:0042742 defense response to bacterium
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045408 regulation of interleukin-6 biosynthetic process
GO:0045410 positive regulation of interleukin-6 biosynthetic process
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0070339 response to bacterial lipopeptide
GO:0070340 detection of bacterial lipopeptide
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071220 cellular response to bacterial lipoprotein
GO:0071221 cellular response to bacterial lipopeptide
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071725 response to triacyl bacterial lipopeptide
GO:0071727 cellular response to triacyl bacterial lipopeptide
GO:0098542 defense response to other organism
GO:0098543 detection of other organism
GO:0098581 detection of external biotic stimulus
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
Molecular Function GO:0033218 amide binding
GO:0035325 Toll-like receptor binding
GO:0035663 Toll-like receptor 2 binding
GO:0042277 peptide binding
GO:0046982 protein heterodimerization activity
GO:0071723 lipopeptide binding
Cellular Component GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030670 phagocytic vesicle membrane
GO:0035354 Toll-like receptor 1-Toll-like receptor 2 protein complex
GO:0043235 receptor complex
GO:0045121 membrane raft
GO:0045335 phagocytic vesicle
GO:0098589 membrane region
GO:0098802 plasma membrane receptor complex
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04620 Toll-like receptor signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-6803157: Antimicrobial peptides
R-HSA-1461957: Beta defensins
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1461973: Defensins
R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-1236974: ER-Phagosome pathway
R-HSA-5603041: IRAK4 deficiency (TLR2/4)
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-5602498: MyD88 deficiency (TLR2/4)
R-HSA-166058: MyD88
R-HSA-5686938: Regulation of TLR by endogenous ligand
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TLR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TLR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27267778MelanomaPromote immunityCombining TLR1-TLR2 ligand with an agonistic antibody to 4-1BB enhanced the antitumor activity in mice with established melanoma tumors. These studies reveal that the costimulatory effects of TLR1-TLR2 signaling in CD8(+) T cells are in part mediated by 4-1BB and are important for mounting an effective antitumor immune response.
24799523LymphomaPromote immunityWe treated B-cell lymphoma cells with the TLR1/2 agonist Pam3CSK4 and the genotoxic anticancer agent 1-β-D-arabinofuranosylcytosine (Ara-C). The treatment of B-cell lymphoma cells with the TLR1/2 agonist Pam3CSK4 enhanced the anticancer effects of the genotoxic agent Ara-C. Mice injected with cotreated tumor cells survived longer than mice challenged with Pam3CSK4 or Ara-C-treated cells. Administration of Pam3CSK4 or Ara-C reduced the tumor load of mice injected with tumor cells.
Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TLR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TLR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5590.2
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5790.629
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5510.513
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1550.747
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4480.784
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2180.918
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4080.354
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4270.731
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3410.812
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1430.345
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4780.44
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0720.671
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TLR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TLR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TLR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TLR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TLR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TLR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TLR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTLR1
Nametoll-like receptor 1
Aliases rsc786; KIAA0012; CD281; TIL; TIL. LPRS5; toll/interleukin-1 receptor-like protein; CD antigen CD281
Chromosomal Location4p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TLR1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.